Engineering The Next Wave Of CHO Performance With S-CHOice® 2G Platform

By Wookjae Lee, Lead Scientist in the Molecular Biotechnology; and Migyeom Kim, Lead Scientist in the Cellular Engineering

The global demand for advanced biologics is accelerating at an unprecedented pace, driven by expanding therapeutic applications and growing patient needs. At the same time, developers face increasing pressure to shorten development timelines while controlling rising costs. In this highly competitive and resource-intensive landscape, cell line development (CLD) has emerged as a pivotal factor in determining not only manufacturability and scalability but also the long-term commercial viability of biologic products.

Recognizing these challenges, Samsung Biologics has advanced its capabilities by building on the success of its first-generation platform. Its S-CHOice® 2G cell line technology represents a significant evolution, offering enhanced performance and efficiency. This next-generation platform delivers higher average antibody productivity, enabling greater yield from the same production footprint. In parallel, it supports accelerated development timelines, allowing programs to move more quickly from early-stage development to clinical and commercial manufacturing.

By combining improved productivity with speed and reliability, S-CHOice® 2G helps biopharmaceutical companies optimize their manufacturing strategies, reduce overall costs, and respond more effectively to market demands. Ultimately, it provides a robust foundation for more efficient, scalable, and competitive biologics production in an increasingly dynamic global market.